	Application No.	Applicant(s)
Notice of Allowability	10/510,923	YOON ET AL.
	Examiner	Art Unit
	Amelia A. Owens	1625
The MAILING DATE of this communication app All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT I of the Office or upon petition by the applicant. See 37 CFR 1.31	S (OR REMAINS) CLOSED in 5) or other appropriate commu RIGHTS. This application is s 13 and MPEP 1308.	this application. If not included inication will be mailed in due course. THIS
1. This communication is responsive to <u>amdt filed 1/19/2006</u>	<u>6</u> .	
2. The allowed claim(s) is/are <u>1-4 and 6</u> .		
 3. Acknowledgment is made of a claim for foreign priority to a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have a copies of the priority documents. 	ve been received. ve been received in Applicatio	n No
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
 DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. 		
Attachment(s) 1. ☑ Notice of References Cited (PTO-892)	5. ☐ Notice of Inf	ormal Patent Application (PTO-152)
2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Su	ummary (PTO-413),
3. Information Disclosure Statements (PTO-1449 or PTO/SB/	Paper No./l (08), 7. ☐ Examiner's ا	Mail Date Amendment/Comment
Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit		Statement of Reasons for Allowance
of Biological Material	9. ⊠ Other <u><i>NO D</i></u>	RAWINGS.

Art Unit: 1625

Application/Control Number: 10/510,923

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance:

- 1. Claim 5 ahs been canceled. Claim 6 has been added. Claims 1-4,6 are pending.
- 2. The rejection of claims 1-4 under 35 USC 112, 2nd paragraph is dropped as the claims have been amended.
- 3. The rejection of claims 4,5 under 35 USC 102(b) has been dropped as the claims have been amended and/or canceled thereby creating a clear demarcation over the art.
- 4. Acetlcholinesterase (AchE) inhibitors are known and used as therapeutic agents of dementia by enhancing cognition. See specification @ page 2 lines 11-20 that lists several AchE agents currently in use. See Ringman, Metrifonate: update on a new antidementia agent, PMID: 10584768; Doody, Clinical benefits of a new piperidine-clas AchE inhibitor, PMID: 10332937. Thus the skilled artisan is aware of the nexus between AchE inhibitors and enhancing cognition.

The data in the specification is noted. Experiment 2 @ page 13 demonstrate compound 3 of the invention and decursin have AchE inhibitory activity. Thus, the skilled artisan knowing AchE inhibitors enhance cognition would expect the claimed compounds which exhibit AchE inhibitory activity to enhance cognition.

5. The prior art neither teaches nor suggests the claimed compounds. In the absence of any evidence or apparent reason why the claimed compounds do no possess the disclosed utility, the allegation of utility in the specification must be accepted as correct. In re Kamal et al, 158 USPO 320; Ex parte Krenzer, 199 USPQ 227.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

÷

Application/Control Number: 10/510,923

Art Unit: 1625

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amelia A. Owens whose telephone number is 571-272-0690. The examiner can normally be reached on Monday - Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia J. Tsang can be reached on 571-272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197. (toll-free).

Amelia A. Owens
Primary Examiner
Art Unit 1625

Page 3